AstraZeneca Pharma India Limited has announced that it will launch Sodium Zirconium Cyclosilicate powder for oral suspension 5g (Lokelma) in November 2025, marking the company’s latest addition to its renal care portfolio.
The company had earlier, on March 6, 2025, received Import and Marketing Permission in Form CT-20 from the Drugs Controller General of India (DCGI) for Lokelma in 5g and 10g formulations. Lokelma is indicated for the treatment of hyperkalemia in adult patients, a condition characterized by elevated potassium levels in the blood, which can be life-threatening if untreated.
The upcoming launch underscores AstraZeneca’s continued focus on addressing critical unmet medical needs in India, especially in the cardiovascular and renal therapy segments.
Disclaimer: The information provided is for informational purposes only and should not be considered medical, financial, or investment advice. Consult a licensed healthcare professional before making medical decisions.
